Beacon raises $170M to take on J&J in ocular gene therapy

Kyle LaHucik

Senior Reporter

Transatlantic biotech Beacon Therapeutics has raised $170 million to potentially bring a rare ophthalmology gene therapy to market in a competition with Johnson & Johnson …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Beacon raises $170M to take on J&J in ocular gene therapy

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bea­con rais­es $170M to take on J&J in oc­u­lar gene ther­a­py

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Beacon raises $170M to take on J&J in ocular gene therapy